$XBI $146.95 +4% 📈
Want to access our searchable database of 900 catalysts and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$VIR +32% and $GSK Announced phase 3 results that VIR-7831 reduces hospitalizations and risk of death in early treatment of adults with Covid-19 after IDMC recommended trial stop early due to efficacy. source
$CYDY +15% Phase 2 trial enrolled 20 patients in 10 days, enrollment to be completed this month. source
$RIGL +8% Completes enrollment for trial in hospitalized covid-19 patients. Data expected in April 2021. source
$PDSB +40% Covid-19 vaccine Consortium received commitment from The Ministry of Science of Brazil to fund clinical development. source
Pipeline Updates
$BHVN +5% Completed 50% enrollment ahead of timeline in ph2/3 trial of verdiperstat in ALS. source
$BHVN +5% Nurtec ODT approved in United Arab Emirates for acute treatment of migrain. source
$BTAI +4% NDA submitted for BXCL501 for agitation associated with schizo and BD. FDA decision expected by 5/10/21. source
$SPPI +19% FDA grants Fast Track Designation for poziotinib for the treatment of NSCLC in previously treated patients with HER2 exon 20 mutations. NDA expected to be submitted later this year. source
$ALKS +2% FDA grants Orphan Drug Designation to nemvaleukin alfa for the treatment of mucosal melanoma. source
$PHAS +10% Enters into supply agreement to support development and commercialization of bentracimab with BioVectra Inc. source
Finance Updates
$ENDP +6% Private offering